of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Chief Financial Officer and Treasurer — Jason Faessler: Quanterix Corporation has appointed Jason Faessler as the Chief Financial Officer and Treasurer.

Chief Operating Officer — Anthony Catalano: Mr. Catalano was appointed as the Chief Operating Officer of Quanterix Corporation from an external position.

Chief Financial Officer and Treasurer — Vandana Sriram: Ms. Sriram is leaving the company and no successor has been named yet.

of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. On March 2, 2026, Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 (the “Earnings Release”). A copy of the Earnings Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

of this Form 8-K (including the portion of Exhibit 99.1 that discusses Quanterix’s expectations regarding certain financial results for the fiscal year ended December 31, 2025) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except a…

President and Chief Executive Officer — Masoud Toloue, Ph.D.: Dr. Masoud Toloue resigned as President and CEO with a successor appointed.

Director — Paul Meister and David Walt, Ph.D.: Two directors retired and were replaced by two new directors.

of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry Into a Material Definitive Agreement. On August 4, 2025, Quanterix Corporation (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”), by and between the Company, on the one hand, and Kent Lake PR LLC, a Puerto Rico limited liability company and the general partner of Kent Lake Partners LP, a Delaware limited partnership (together, “Kent Lake”), on the other hand. In accordance with the terms of the Cooperation Agreement, the Company has agreed to retain an e…

of Form 8-K, the Company will file an amendment to this report if charges and future cash payments differ materially from current estimates. Forward-Looking Statements Certain statements in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to expectations concerning matters that are not historical facts. Such for…

of Form 8-K, the Company will file an amendment to this report if charges and future cash payments differ materially from current estimates. Forward-Looking Statements Certain statements in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to expectations concerning matters that are not historical facts. Such for…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On May 9, 2025, Quanterix Corporation (the “Company”) dismissed Ernst and Young LLP (“EY”) as its independent registered public accounting firm, to be effective following the filing of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025. This change in the Company’s independent registered public accounting firm was approved by the Audit Committee…

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of Form 8-K, Quanterix will file an amendment to this report if charges and future cash payments differ materially from current estimates. IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix (the “Merger”), Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a post-effective amendment to its registration statement on Form S-4 (as amended, the “Registration Statement”), which will contain a…

and shall not be deemed to be “filed” for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”). Important Additional Information In connection with the proposed Merger, Quanterix will file with the SEC a post-effective amendment to its registration statement on Form S-4 (as so amended, the “Registration Statement”)…

Entry into a Material Definitive Agreement. Amended and Restated Agreement and Plan of Merger On April 28, 2025, Quanterix Corporation, a Delaware corporation (the “ Company ” or “ Quanterix ”), entered into an Amended and Restated Agreement and Plan of Merger (the “ A&R Merger Agreement ”), by and among the Company, Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Akoya Biosciences, Inc., a Delaware corporation (“ Akoya ”), p…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 2, 2025, Quanterix Corporation (“Quanterix”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Akoya Biosciences, Inc. (“Akoya”), pursuant to which Akoya will issue and sell to Quanterix from time to time, in a private placement, one or more convertible promissory notes having an aggregate principal amount of up to $30,000,000 (the “Convertible Notes”). Akoya may draw on th…

Chairman of the Board — Martin D. Madaus, Ph.D.: Dr. Madaus resigned from the Board following his receipt of less than a majority of votes cast in support of his reelection.

Results of Operations and Financial Condition. On March 17, 2025, Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 (the “Earnings Release”). A copy of the Earnings Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the…

Regulation FD Disclosure. On March 3, 2025, Quanterix Corporation (the “ Company ” or “ Quanterix ”) issued a press release highlighting the benefits of its proposed acquisition of Akoya Biosciences, Inc. (“ Akoya ”) pursuant to the terms of the Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Wellfleet Merger Sub, Inc., a wholly owned subsidiary of the Company, and Akoya (the “ Merger ”). The Company also commented on a notice submitted by Kent Lake Partners…

Other Events. As previously disclosed, on January 9, 2025, Quanterix Corporation, a Delaware corporation (the “ Company ” or “ Quanterix ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Akoya Biosciences, Inc., a Delaware corporation (“ Akoya ”), pursuant to which, subject to the terms and conditions set forth therein, Merger…

The filing describes the approval of an annual cash incentive plan for executive officers.